title: Prostaglandin E2 enhances transforming growth factor-beta 1 and TGF-beta receptors synthesis: an in vivo and in vitro study.
abstract: The aims of this study were to determine how Prostaglandin E2 (PGE2) locally applied affected the immunodistribution of latent transforming growth factor-beta 1 (TGF-beta1), and how the eicosanoid modified TGF-beta1 release and TGF-beta receptors gene expression in cultured osteoblasts. PGE2 locally delivered on the rat mandible at doses of 0.1 and 0.05 mg/day, but not 0.025 mg/day, over 20 days significantly increased latent TGF-beta1 immunodistribution (P<0.001), comparing with a placebo-treated group. Cultured osteoblasts stimulated with 10(-5) or 10(-7)M PGE2 significantly varied the level of activated TGF-beta1 released into supernatants at different experimental periods compared with negative and positive controls. TGF-beta receptor type I gene expression was significantly increased in osteoblasts (P<0.01) after 10 days of treatment with 10(-5) and 10(-7)M PGE2, whereas 10(-3) M PGE2 produced the opposite effect. It is concluded that PGE2 may stimulate bone deposition by affecting TGF-beta pathway. This effect on the pathway appears to be dose-dependent.
authors.affiliation: Oral Biology & Pathology, School of Dentistry, The University of Queensland, St. Lucia Campus, Brisbane, Qld. 4072, Australia. g.ramirez@uq.edu.au
authors.forename: G O
authors.initials: GO
authors.lastname: Ramirez-Yañez
authors.forename: S
authors.initials: S
authors.lastname: Hamlet
authors.forename: A
authors.initials: A
authors.lastname: Jonarta
authors.forename: G J
authors.initials: GJ
authors.lastname: Seymour
authors.forename: A L
authors.initials: AL
authors.lastname: Symons
mesh_terms: D030201:Activin Receptors, Type I / Q000235:genetics; D000469:Alkaline Phosphatase / Q000032:analysis; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002478:Cells, Cultured; D050659:Core Binding Factor Alpha 1 Subunit / Q000032:analysis; D017077:Culture Media, Conditioned / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D015232:Dinoprostone / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D020007:Implants, Experimental; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases; D051381:Rats; D011917:Rats, Inbred Lew; D017208:Rats, Wistar; D000077293:Receptor, Transforming Growth Factor-beta Type I; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D016212:Transforming Growth Factor beta / Q000032:analysis / Q000378:metabolism*; D053773:Transforming Growth Factor beta1
chemical_list: D050659:Core Binding Factor Alpha 1 Subunit; D017077:Culture Media, Conditioned; D003692:Delayed-Action Preparations; D018125:Receptors, Transforming Growth Factor beta; C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D017346:Protein Serine-Threonine Kinases; D030201:Activin Receptors, Type I; D000077293:Receptor, Transforming Growth Factor-beta Type I; D000077294:Receptor, Transforming Growth Factor-beta Type II; C000625843:Tgfbr1 protein, rat; D000469:Alkaline Phosphatase; D015232:Dinoprostone